DUBLIN–(BUSINESS WIRE)–The “Acute Bacterial Skin and Skin Structure Infections Market, by Drug Type, by Infection Type, by Route of Administration, by Distribution Channel, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering.
Acute bacterial skin and skin structure infections are a collection of common types of infection including abscesses, cellulitis, and wound infections, which requires an immediate effective antibacterial treatment as part of a timely and careful management.
Drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus causing acute bacterial skin and skin structure infections are more challenging to treat due to lack of availability of effective antibiotics. Acute bacterial skin and skin structure infections may be acquired through hospitals, as well as community. Methicillin-resistant Staphylococcus aureus may appear in a community among younger people who had not been previously exposed to hospitals or healthcare institutions, who may instead have been colonized through sporting activities, crowding, and intravenous drug abuse.
Market Dynamics
Market players are acquiring drug distribution rights in various countries, which is expected to drive the global acute bacterial skin and skin structure infections market, over the forecast period. For instance, in March 2020, Sandoz, a pharmaceutical company acquired distribution rights of daptomycin 500mg injection and fosaprepitant 150mg for injection in the U.S. from BE Pharmaceuticals, a pharmaceutical company. This step was taken to strengthen the company’s plan to grow its injectable portfolio and contributions in the hospital. Daptomycin is a naturally occurring lipopeptide antibiotic used in the treatment of acute bacterial skin and skin structure infections.
Increasing research and development by the key players for the development of new drugs to treat global acute bacterial skin and skin structure infections is expected to propel growth of the global acute bacterial skin and skin structure infections market. For instance, on September 28, 2020, TenNor Therapeutics Limited, a global clinical-stage company completed Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TNP-2092 to treat acute bacterial skin and skin structure infection in adults. TNP-2092 was compared to vancomycin in a double-blind randomized, phase-II clinical trial for the treatment of confirmed or suspected Gram-positive ABSSSI. The study has been completed, and results are awaited.
Detailed Segmentation:
Global Acute Bacterial Skin and Skin Structure Infections Market, By Drug Type:
Oral & Parenteral Antibiotics
Oritavancin
Delafloxacin
Vancomycin
Daptomycin
Dalbavancin
Ceftaroline
Linezolid
Tedizolid
Clindamycin
Others (Rifampin, Doxycycline, Minocycline, Trimethoprim-Sulfa Methoxazol, etc.)
Topical Antibiotics
Hydrogen Peroxide
Fusidic Acid
Mupirocin
Retapamulin
Povidone-Iodine
Global Acute Bacterial Skin and Skin Structure Infections Market, By Infection Type:
Hospital Acquired ABSSSI
Community Acquired ABSSSI
Global Acute Bacterial Skin and Skin Structure Infections Market, By Route of Administration:
Oral
Parenteral
Topical
Global Acute Bacterial Skin and Skin Structure Infections Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Acute Bacterial Skin and Skin Structure Infections Market, By Region:
North America
U.S.
Canada
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Europe
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
South Africa
Central Africa
North Africa
Company Profiles
Fresenius SE & Co. KGaA
Pfizer, Inc.
Amneal Pharmaceuticals LLC
Intas Pharmaceuticals Ltd.
Cadila Healthcare Ltd.
Glenmark Pharmaceuticals Ltd,
GlaxoSmithKline plc.
Sun Pharmaceutical Industries Ltd.
Sandoz Inc.
Aurobindo Pharma Ltd.
AbbVie, Inc.
Melinta Therapeutics, Inc.
Accord Healthcare Ltd.
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Paratek Pharmaceuticals, Inc.
Key Topics Covered:
1. Research Objectives and Assumptions
2. Market Overview
3. Market Dynamics, Regulations, and Trends Analysis
4. Global Acute Bacterial Skin and Skin Structure Infections Market- Impact of Coronavirus (Covid-19) Pandemic
5. Global Acute Bacterial Skin and Skin Structure Infections Market, By Drug Type, 2017-2030 (US$ Million)
6. Global Acute Bacterial Skin and Skin Structure Infections Market, By Infection Type, 2017 – 2030 (US$ Million)
7. Global Acute Bacterial Skin and Skin Structure Infections Market, By Route of Administration, 2017 – 2030 (US$ Million)
8. Global Acute Bacterial Skin and Skin Structure Infections Market, By Distribution Channel, 2017 – 2030 (US$ Million)
9. Global Acute Bacterial Skin and Skin Structure Infections Market, By Region, 2017 – 2030 (US$ Million)
10. Competitive Landscape
11. Section
For more information about this report visit https://www.researchandmarkets.com/r/rb0mwm
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
